Cipla recalls 4,800 bottles of anti-HIV tablets from US
Drug major Cipla is recalling 4,800 bottles of Nevirapine extended-release tablets used for the treatment of human immunodeficiency virus (HIV) from the American market, according to a report by the US health regulator.
As per the latest Enforcement Report by the United States Food and Drug Administration (USFDA), the reason for the recall of the bottles is 'failed dissolution specifications'.
Read Also: Cipla gets USFDA nod for anti-viral eye infection drug for AIDS patients
Nevirapine extended-release tablets, 400 mg in the 30-count bottle have been manufactured by Cipla at its Goa facility for Cipla USA Inc, it added.
The US health regulator has not yet classified the voluntary recall by the company, the report said.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd